Secondary hypertension in patients with saccular intracranial aneurysm disease: A population based study

Satu Kotikoski1, Jukka Huttunen1, Terhi J. Huttunen1, Katarina Helin1, Juhana Frösen1, Timo Koivisto1, Mitja Kurki1, Mikael von und zu Fraunberg1, Ilkka Kunnamo2, Juha E. Jääskeläinen1*, Antti E. Lindgren1,3*

1 Neurosurgery of NeuroCenter, Kuopio University Hospital, and Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland, 2 The Finnish Medical Society Duodecim, Helsinki, Finland, 3 Department of Neurology and Neurosurgery, UMC Utrecht, Utrecht, the Netherlands

* These authors contributed equally to this work.
* antti.lindgren@kuh.fi

Abstract

Background

Secondary hypertension is a serious form of hypertension, involving 5% to 10% of all hypertension patients. Hypertension is a risk factor of the saccular intracranial aneurysm (sIA) disease and subarachnoid hemorrhage from ruptured sIA (aSAH), but the impact of secondary hypertension on sIA disease is poorly known. In a defined Eastern Finnish sIA population we studied the prevalence of secondary hypertension and its impact on sIA disease phenotype.

Methods

We included 2704 consecutive sIA patients first admitted to Kuopio University Hospital from 1995 to 2014. Their clinical data from Kuopio Intracranial Aneurysm patient and Family Database was fused with prescription drug usage data, hospital diagnoses and causes of death, retrieved from nationwide registries. Medical records of hypertensive sIA patients were reviewed to confirm or exclude secondary hypertension. Prevalence of secondary hypertension and associated diagnoses were calculated. Logistic regression was used to identify clinical characteristics of sIA disease that associated with secondary hypertension.

Results

We identified 2029 (75%) sIA patients with hypertension and 208 (10%) of them had secondary hypertension. Most frequent conditions associated with secondary hypertension were kidney and renovascular diseases (45%), sleep apnea (27%) and hypothyroidism (19%); 46 (22%) of the 208 patients had more than one such condition. In multivariate logistic regression analyses of 1561 aSAH patients, secondary hypertension significantly
and Family Database board has granted permission for data access. We did not have special privileges to access data from the Institute of Health and Welfare, and other qualified researchers will be able to access the data in the same manner as we did. Research coordinator of Kuopio Intracranial Aneurysm Patient and Family Database board can be contacted via web form in http://kuopioneurosurgery.fi/research-group/#donation-box. Authorization to access data of Institute of Health and Welfare can be applied for at https://thl.fi/en/web/thlfi-en/statistics/information-for-researchers/authorisation-application.

**Funding:** The study was supported by North Savo Regional Fund of the Finnish Cultural Foundation, the Saastamoinen Foundation, the Juho Vainio foundation, the Päivikki and Sakari Sohlberg Foundation, Finnish Academy of Sciences, and Kuopio University Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

associated with the number of sIAs (\(p = 0.003; \text{OR } 1.32; 95\% \text{ CI } 1.10--1.58\)) and male gender (\(p = 0.034; \text{OR } 1.59; 95\% \text{ CI } 1.04--2.43\)).

**Conclusions**

Secondary hypertension was relatively common (10%) among hypertensive sIA patients. Secondary causes for hypertension should be taken into account in hypertensive sIA patients, especially in aSAH patients with multiple intracranial aneurysms. Further research is indicated to evaluate the impact of secondary hypertension on the long-term rupture risk of unruptured sIA carriers and long-term outcome after aSAH.

**Introduction**

The prevalence of saccular intracranial aneurysm (sIA) disease in general population is around 3% [1]. Most sIAs do not cause symptoms and remain unnoticed during life [2], if not incidentally found in neuroimaging for other reasons or by screening sIA families [3]. Aneurysmal subarachnoid hemorrhage (aSAH), most often caused by rupture of sIA wall, is a severe form of stroke with high mortality and neurological morbidity [4–10]. Known risk factors for sIA disease and aSAH include female gender, age, smoking, hypertension, sIA family, and autosomal polycystic kidney disease (ADPKD) [2, 9–14].

Secondary hypertension, resulting from an underlying identifiable cause, is a more serious form of hypertension, involving about 5% to 10% of all hypertension patients [15–18]. Etiologies for secondary hypertension include chronic kidney diseases [19], renovascular hypertension [20], primary aldosteronism [21], and obstructive sleep apnea [22], as well as number of rare causes [17]. Reaching the diagnosis of secondary hypertension is often challenging: indicators include young age, persistent hypertension requiring more than three types of antihypertensive medication, weakened response to previous medications, and exceptionally high blood pressure levels [23, 24]. Proper treatment of secondary hypertension may reduce the risk of serious cardiovascular complications, including heart disease, kidney failure and stroke.

Hypertension is a common risk factor of sIA disease and aSAH [2, 25], but published data on the occurrence and significance of secondary hypertension in sIA patients has remained scarce. The Kuopio Intracranial Aneurysm Patient and Family Database (www.kuopioneurosurgery.fi) contains all cases of unruptured and ruptured sIAs admitted to the Kuopio University Hospital (KUH) from a defined Eastern Finnish catchment population since 1980 [12]. The present study included 2704 sIA patients (1143 unruptured and 1561 ruptured) first admitted to KUH from 1995 to 2014. Their registry data, including the diagnoses, prescribed drugs and causes of deaths, were obtained from the nationwide registries and fused with the clinical data[2,7,8,13]. We retrospectively studied the sIA patients to define the prevalence of secondary hypertension on carriers of sIA disease and its impact on sIA disease phenotype.

**Materials and methods**

**Study population**

Kuopio Intracranial Aneurysm Patient and Family Database. During the study period from 1995 to 2014 KUH Neurosurgery exclusively provided neurosurgical services for a defined KUH catchment population in Eastern Finland. Geographical area remained the same...
but population decreased from 882671 to 840587. The median age increased from 37 to 42 in
males and from 40 to 45 in females, and the proportion of males remained unchanged at 49%
[8, 12].

All patients with verified SAH by CT or spinal tap have been admitted to KUH for angiog-
raphy and treatment if not moribund. Unruptured sIAs have been verified by four-vessel digi-
tal subtraction angiography, magnetic resonance angiography or computed tomography
angiography. Patients with unruptured IAs have also had neurosurgical consultation for the
treatment and follow-up. KUH Neurosurgery maintains a database of all cases ruptured and
unruptured intracranial aneurysms admitted to KUH since 1980. The database has been pro-
spective since 1990 [12]. A dedicated full-time research nurse runs the database, interviews all
new cases, and collects and codes detailed information into variables, including family history,
defined as at least two affected first-degree relatives [12, 26].

The basic study population included all sIA patients from 1995 to 2014 (Fig 1). The final
study population consisted of unruptured and ruptured sIA patients who met the following
criteria: 1) a citizen of Finland and resident of the KUH catchment area at the first diagnosis of
the sIA disease from 1995 to 2014; 2) verification of the sIA disease with four-vessel angiogra-
phy; 3) patients with other types of IAs (fusiform, traumatic, mycotic) excluded (Fig 1).

**Antihypertensive medication**

The Social Insurance Institution of Finland has since 1994 prospectively maintained a nation-
wide registry for all patients who have purchased prescribed drugs from the pharmacies,
including all antihypertensive drugs. All pharmacies in Finland are included in the prospective
registry. In Finland all antihypertensive drugs are sold in pharmacies by prescription only. The
antihypertensive medication use in the study population of 2704 sIA patients (Fig 1) was ana-
lyzed between January 1, 1995, and December 31, 2014, allowing us to analyze antihyperten-
sive medication use at least one year before the sIA diagnosis. The data contained information
since the first purchase date and the number of purchases until the last date. Purchases of anti-
hypertensive drugs with ATC codes C02 (antihypertensives), C03 (diuretics; thiazides), C04
(peripheral vasodilators), C07 (beta blocking agents), C08 (calcium channel blockers), and
C09 (agents acting on the renin-angiotensin system) were included in the analysis.

**Hospital diagnoses and death records**

All hospital diagnoses (ICD-10), including hypertension diagnoses were obtained from the
Finnish electronic hospital diagnosis registry (Care Register For Health Care HILMO, man-
aged by the Finnish Institution for Health and Welfare) that covers all secondary and tertiary
referral hospitals in Finland and encompasses all medical specialties. Death records and death
diagnoses (ICD-10) were obtained from Statistics Finland. Hospital diagnoses and causes of
death were then fused with the clinical data.

**Diagnosis of hypertension.** We defined hypertension was defined as one of the following:
1) self-proclaimed hypertension; 2) hypertension diagnosis by a physician; or 3) prescribed
antihypertensive medications (Fig 1).

**Diagnosis of secondary hypertension.** Secondary hypertension was suspected in hyper-
tensive sIA patients with one or more concomitant morbidities that associate with suspected
secondary hypertension (Table 1), and their case reports were reviewed to confirm or exclude
secondary hypertension as described in ESH/ESC (European Society of Cardiology http://
www.escardio.org/Guidelines) guidelines [24].
Fig 1. Flowchart of the study population: 2,704 patients with saccular intracranial aneurysm (sIA) disease admitted to the Kuopio University Hospital (KUH) with unruptured sIA disease or first subarachnoid hemorrhage (aSAH) from the Eastern Finnish catchment population from 1995 to 2014. Identification of the hypertensive sIA patients with comorbid diseases suggestive of secondary hypertension.

https://doi.org/10.1371/journal.pone.0206432.g001
Table 1. 208 sIA patients with one or more clinical conditions (n = 260) considered as etiological factors for their secondary hypertension among 2704 sIA patients admitted to Kuopio University Hospital from the Eastern Finnish catchment population in 1995–2014.

| Clinical condition and ICD-10 classification | Patients n = 208 |
|-----------------------------------------------|-----------------|
| **Kidney and renovascular diseases**          |                 |
| Polycystic kidney disease (Q61.2, Q61.3)       | 27 (13%)        |
| Kidney failure (N17-19)                        | 17 (8.2%)       |
| Glomerulonephritis and nephrotic syndrome (N00-N08) | 15 (7.2%)  |
| Diabetic nephropathy (E10.2, E11.2)            | 9 (4.3%)        |
| Hydronephrosis (N13.0, N13.1, N13.3, N13.9)    | 9 (4.3%)        |
| Tubulo-interstitial nephritis and other conditions (N11-12, N14-16) | 6 (2.9%)  |
| Malignant neoplasm of kidney (C64)             | 6 (2.9%)        |
| Atherosclerosis of renal artery (I15.0, I17.0)  | 4 (1.9%)        |
| Fibromuscular dysplasia (I77.3)                | 1 (0.5%)        |
| Coarctation of the aorta (Q25.1)               | 2 (1.0%)        |
| **Adrenal gland diseases**                     |                 |
| Benign or malignant neoplasm of adrenal gland (D35.0, C74) | 6 (2.9%)  |
| Hyperaldosteronism (E26)                       | 2 (1.0%)        |
| **Other hormonal diseases**                    |                 |
| Hypothyroidism (E03)                           | 39 (19%)        |
| Hyperthyroidism (E05)                          | 14 (6.7%)       |
| Hyperparathyroidism (E21.0-E21.3)              | 10 (4.8%)       |
| Benign neoplasm of pituitary gland (D35.2)     | 6 (2.9%)        |
| Acromegaly (E22.0)                             | 2 (1.0%)        |
| **Systemic diseases**                          |                 |
| Sjögren’s syndrome (M35.0)                     | 5 (2.4%)        |
| Familial dysautonomia (Riley–Day syndrome) (G90.1) | 5 (2.4%)  |
| Systemic lupus erythematosus (M32)             | 5 (2.4%)        |
| Other specified or unspecified necrotizing vasculopathy (M31.8, M31.9) | 3 (1.4%)  |
| Amyloidosis (E85) with kidney failure or nephritic syndrome | 2 (1.0%)  |
| Thrombotic microangiopathy (M31.1)             | 2 (1.0%)        |
| Giant cell arteritis (M31.5)                   | 2 (1.0%)        |
| Henoch-Schönlein purpura (D69.0)               | 1 (0.5%)        |
| Rheumatoid vasculitis with rheumatoid arthritis (M05.2) | 1 (0.5%)  |
| Polyrteritis nodosa (M30.0)                    | 1 (0.5%)        |
| Wegener’s granulomatosis (M31.3)               | 1 (0.5%)        |
| Systemic sclerosis (M34)                       | 1 (0.5%)        |
| Sleep apnea (G47.3)                            | 57 (27%)        |

https://doi.org/10.1371/journal.pone.0206432.t001

**Ethical aspects**

This research has been authorized by Kuopio University Hospital Research Ethics Committee. The patient data integration from the nationwide registries to Kuopio IA database was completed with the endorsement from National Institute of Health and Welfare. Written informed consent was obtained from all patients before their data was input to Kuopio Intracranial Patient and Family database.

**Statistical analysis**

Categorical variables were expressed in proportions and continuous variables in medians, quartiles, and ranges. Groups were compared using the Pearson’s Chi-Square ($\chi^2$) test or the
Mann–Whitney U test. Multivariate analyses were performed using logistic regression to calculate odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for having secondary hypertension with gender, age at first diagnosis, familial sIA disease and number sIAs as variables. P values < 0.05 were considered significant. SPSS 22 statistical software was used (SPSS, Inc, Chicago, IL).

Results

The study population consisted of 2704 sIA patients, 1143 (42%) with unruptured sIA disease and 1561 (58%) with aSAH, admitted to KUH between 1995 and 2014 (Fig 1). Their follow-up ended at death (n = 776) or December 2014, with total follow-up of 18751 patient-years and a median follow-up time of 68 months. Table 2 presents the characteristics of the 2704 sIA patients and their 3922 sIAs.

Of the study population, 2029 (75%) sIA patients had hypertension (Fig 1, Table 2) and 208 (10%) of them had secondary hypertension (Table 1). Of the patients with secondary hypertension, 46 (22%) had more than one condition associated with secondary hypertension. The most frequent conditions associated with secondary hypertension were kidney and renovascular diseases (45%), sleep apnea (27%) and hypothyroidism (19%) (Table 1). Of the 208 patients with secondary hypertension 88 (42%) had a positive smoking history.

Table 2. Secondary vs. essential hypertension among 2704 patients with 3922 saccular intracranial aneurysms (sIAs) admitted to Kuopio University Hospital from the Eastern Finnish catchment population in 1995–2014.

| Variables of 2704 sIA patients | Unruptured sIA patients n = 1143 | aSAH patients n = 1561 |
|--------------------------------|----------------------------------|------------------------|
| Hypertension                   | Secondary hypertension n = 111 | No secondary hypertension n = 810 | Secondary hypertension n = 97 | No secondary hypertension n = 1011 | No hypertension n = 453 |
| Median age at sIA diagnosis (quartiles) | 58 (51–65) | 59 (50–68) | 50 (42–57) | 55 (46–65) | 55 (47–65) | 50 (42–60) |
| Females | 64 (58%) | 475 (59%) | 120 (54%) | 48 (50%) | 624 (62%) | 236 (52%) |
| Familial sIA disease | 18 (16%) | 143 (18%) | 49 (22%) | 16 (16%) | 105 (10%) | 36 (8%) |
| Multiple sIAs (≥2) | 32 (29%) | 236 (29%) | 56 (25%) | 35 (36%) | 310 (31%) | 117 (26%) |
| Known positive smoking history | 40 (36%) | 351 (43%) | 108 (49%) | 48 (49%) | 427 (42%) | 193 (43%) |

| Variables of 3922 sIAs | Hypertension | | Hypertension |
|------------------------|--------------|--------------|--------------|
| Hypertension           | Secondary hypertension n = 160 | No secondary hypertension n = 1148 | Secondary hypertension n = 170 | No secondary hypertension n = 1502 | No hypertension n = 639 |
| Median size (mm) (quartiles) | 4 (3–7) | 4 (3–7) | 4 (3–6) | 4 (3–7) | 5 (3–8) | 6 (3–8) |
| ACoA location | 25 (16%) | 166 (14%) | 34 (11%) | 39 (23%) | 376 (25%) | 148 (23%) |
| Mbif location | 55 (34%) | 442 (39%) | 119 (39%) | 58 (34%) | 433 (29%) | 175 (27%) |
| ICA location | 32 (20%) | 263 (23%) | 88 (29%) | 38 (22%) | 321 (21%) | 164 (26%) |
| Ba bif location | 6 (4%) | 62 (5%) | 10 (3%) | 8 (5%) | 71 (5%) | 24 (4%) |
| Other location | 42 (26%) | 215 (19%) | 52 (17%) | 27 (16%) | 301 (20%) | 128 (20%) |
| Irregular shape | 33 (21%) | 271 (24%) | 83 (27%) | 87 (51%) | 932 (62%) | 417 (65%) |
| Smooth shape | 126 (79%) | 861 (75%) | 210 (69%) | 80 (47%) | 525 (35%) | 188 (29%) |
| Unknown shape | 1 (1%) | 16 (1%) | 10 (3%) | 3 (2%) | 45 (3%) | 34 (5%) |

Abbreviations: sIA = saccular intracranial aneurysm; aSAH = subarachnoid hemorrhage from ruptured sIA; ACoA = anterior communicating artery; Mbif = middle cerebral artery bifurcation; ICA = internal carotid artery; Ba bif = basilar artery bifurcation.

https://doi.org/10.1371/journal.pone.0206432.t002
In the 111 unruptured sIA patients, the median ages (25% and 75% quartiles) at diagnoses were 50 (43–58) years for hypertension, 54 (42–62) years for secondary hypertension causing condition and 58 (51–65) years for unruptured sIA disease. In the 97 aSAH patients, the median ages (25% and 75% quartiles) at diagnoses were 50 (43–61) years for hypertension, 52 (40–67) years for secondary hypertension causing condition and 55 (46–65) years for aSAH.

In total, we identified 26 (13%) carriers of autosomal dominant polycystic kidney disease (ADPKD), while other heritable traits predisposing to hypertension were rare: 5 (2.4%) patients with familial dysautonomia (Riley–Day syndrome).

Of the 367 familial sIA patients, 282 (77%) had the hypertension diagnosis and 34/282 (12%) had secondary hypertension. Of the 2337 sporadic sIA patients, 1747 (75%) had hypertension diagnosis and 174/1747 (10%) had secondary hypertension.

In multivariate logistic regression analyses of aSAH 1561 patients, secondary hypertension significantly associated with the number of sIAs (p = 0.003; OR 1.32; 95% CI 1.10–1.58) and male gender (p = 0.034; OR 1.59; 95% CI 1.04–2.43) (Table 3). For the 1143 unruptured sIA patients, no significant associations with secondary hypertension were found.

Discussion

In this population-based retrospective study of 2704 sIA patients, we showed that 75% had hypertension and 10% of them were considered to have secondary hypertension, with renovascular diseases, sleep apnea and hypothyroidism as most common associated disorders. Interestingly, secondary hypertension significantly associated with the number of sIAs in aSAH patients.

In general Finnish population, the prevalence of secondary hypertension among all hypertension patients has been estimated to be 5–10% in the Finnish national hypertension treatment guideline [27], in line with our results. This estimate is based on two Swedish studies [15–16]: The prevalence of secondary hypertension was 5.8% in a prospective random population sample of 7455 Swedish men [15] and 4.7% in a retrospective study of 1000 hypertension patients sent to a hypertension clinic due to treatment-resistant or newly diagnosed hypertension [16]. In a prospective Japanese study from 2003, the prevalence of secondary hypertension was 9.1% in 1020 hypertensive general outpatient clinic visitors [17]. Possible etiological conditions included aldosteronism (6%), Cushing’s syndrome (1%), preclinical Cushing’s syndrome (1%), pheochromocytoma (0.6%) and renovascular hypertension (0.5%). Importantly, the patients with unspecified renal failure were excluded from the study and no data on sleep apnea or hypothyroidism was given. Hypothyroidism and sleep apnea were frequent in secondary hypertension patients with IAs in our population, which is in line the prevalence estimates of 3.1% [28] for hypothyroidism in and 3.8% [29] for sleep apnea in general European population.

Our study has several strengths derived from the Finnish health care system. Firstly, Finland is divided into mutually exclusive catchment areas for the KUH and the four other
university hospitals, allowing cohorts that are unselected and minimally biased. Finnish personal identification code system allows the creation of very accurate population and clinical data registries [30] and the linking of the registry data with medical records. Secondly, during the study period (1995–2014), the Kuopio Intracranial Aneurysm and Family Database prospectively collected clinical data according to a standard protocol of all unruptured and ruptured sIA patients since their first admission from the KUH catchment population. All sIAs have been verified with four-vessel angiography, excluding the patients with other types of IAs (traumatic, fusiform and mycotic). Thirdly, in Finland, all anti-hypertensive medications are exclusively sold by the physicians’ prescriptions in the pharmacies, and all prescribed drug purchases were retrieved from the national registry encompassing all pharmacies in Finland. Furthermore, the study period 1995–2014 allowed the assessment of prescription drug usage at least one year before sIA diagnosis.

Our study also has weaknesses. Firstly, our study is a retrospective registry-based study. We did not invite patients for clinical visits to be screened for secondary hypertension. The method we used to diagnose secondary hypertension may be insensitive even though it was based on thorough review medical records and combination of comprehensive nationwide registries. It is likely that we have missed patients with secondary hypertension and the actual prevalence may be even higher. Secondly, in some cases the diagnoses associated with secondary hypertension may not have been causes for hypertension, but coincidental findings. Furthermore, due to the method used, we were not able to determine the severity of hypertension. However, we feel that our large study population analyzed with a consistent method to identify patients with secondary hypertension compensates for this limitation. Moreover, identifying definite causative relations in secondary hypertension is difficult regardless of the method used.

Conclusion

In conclusion, we found that secondary hypertension is a relatively common disease in patients with sIA disease, with 10% prevalence in hypertensive sIA carriers. In clinical practice, secondary hypertension may be an overlooked risk factor in patients with subarachnoid hemorrhage. Our results indicate that secondary causes for hypertension should be taken into account in hypertensive sIA patients, especially in aSAH patients with multiple intracranial aneurysms. In these patients, screening for kidney and thyroid disorders and sleep apnea should be considered if hypertension is diagnosed. Further research is indicated to evaluate the impact of secondary hypertension on the long-term rupture risk of unruptured sIA carriers and long-term outcome after subarachnoid hemorrhage.

Acknowledgments

We thank Virve Kärkkäinen, PhD, for her skillful assistance during the drafting of this manuscript.

Author Contributions

Conceptualization: Antti E. Lindgren.

Data curation: Jukka Huttunen, Katariina Helin, Timo Koivisto, Mikael von und zu Fraunberg, Antti E. Lindgren.

Formal analysis: Satu Kotikoski, Antti E. Lindgren.

Investigation: Satu Kotikoski, Antti E. Lindgren.
Project administration: Antti E. Lindgren.

Resources: Katariina Helin, Mikael von und zu Fraunberg.

Software: Mikael von und zu Fraunberg.

Supervision: Timo Koivisto, Mikael von und zu Fraunberg, Juha E. Jääskeläinen, Antti E. Lindgren.

Writing – original draft: Satu Kotikoski, Juha E. Jääskeläinen, Antti E. Lindgren.

Writing – review & editing: Jukka Huttunen, Terhi J. Huttunen, Juhana Frösen, Timo Koivisto, Mitja I. Kurki, Mikael von und zu Fraunberg, Ilkka Kunnamo, Juha E. Jääskeläinen, Antti E. Lindgren.

References

1. Vlak MH, Algra A, Brandenburg R, Rinkel GJ. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: A systematic review and meta-analysis. Lancet Neurol 2011; 10:262–236.

2. Lindgren AE, Kurki MI, Riihinen A, Koivisto T, Ronkainen A, Rinne J, et al. Hypertension predisposes to the formation of saccular intracranial aneurysms in 467 unruptured and 1053 ruptured patients in Eastern Finland. Annals of Medicine 2014; 46:169–176. https://doi.org/10.3109/07853890.2014.883168 PMID: 24579936

3. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. The New England Journal of Medicine 2007; 357:1821–1828. https://doi.org/10.1056/NEJMoa070972 PMID: 17978290

4. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369:306–318. https://doi.org/10.1016/S0140-6736(07)60153-6 PMID: 17258671

5. Karamanakos PN, von Und Zu Fraunberg M., Bendel S, Huttunen S, Kurki M, Hernesniemi J, et al. Risk factors for three phases of 12-month mortality in 1657 patients from a defined population after acute aneurysmal subarachnoid hemorrhage. World Neurosurgery 2012; 78:631–639. PMID: 22120293

6. Huttunen T, von und Zu Fraunberg M., Koivisto T, Ronkainen A, Rinne J, Sankila R, et al. Long-term excess mortality of 244 familial and 1502 sporadic one-year survivors of aneurysmal subarachnoid hemorrhage compared with a matched Eastern Finnish catchment population. Neurosurgery 2011; 68:20–27. https://doi.org/10.1227/NEU.0b013e31827f0fbb PMID: 21099703

7. Huttunen J, Kurki MI, von Und Zu Fraunberg M., Koivisto T, Ronkainen A, Rinne J et al. Epilepsy after aneurysmal subarachnoid hemorrhage: A population-based, long-term follow-up study. Neurology 2015; 84:2229–2237. https://doi.org/10.1212/WNL.0000000000001643 PMID: 25948726

8. Huttunen J, Lindgren A, Kurki MI, Huttunen T, Frösen J, von und zu Fraunberg M., et al. Antidepressant use after aneurysmal subarachnoid hemorrhage: A population-based case-control study. Stroke 2016; 47:2242–2248. https://doi.org/10.1161/STROKEAHA.116.014327 PMID: 27486167

9. Korja M, Silventoinen K, Laatikainen T, Jousilahti P, Salomaa V, Kaprio J. Cause-specific mortality of 1-year survivors of subarachnoid hemorrhage. Neurology 2013; 80:481–486. https://doi.org/10.1212/WNL.0b013e3182770fb5 PMID: 23303843

10. Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurology 2011; 10:349–356. https://doi.org/10.1016/S1474-4422(11)70017-5 PMID: 21435599

11. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett D.A., van Gijn J., Anderson CS. Risk factors for subarachnoid hemorrhage: An updated systematic review of epidemiological studies. Stroke 2005; 36:2773–2780. https://doi.org/10.1161/01.STR.0000190838.02954.e8 PMID: 16282541

12. Huttunen T, von und zu Fraunberg M., Frösen J, Lehecka M, Tromp G, Helin K, et al. Saccular intracranial aneurysm disease: Distribution of site, size, and age suggests different etiologies for aneurysm formation and rupture in 316 familial and 1454 sporadic Eastern Finnish patients. Neurosurgery 2010; 66:631–638. https://doi.org/10.1227/01.NEU.0000367634.89364.4B PMID: 20190670

13. Lindgren AE, Kurki MI, Riihinen A, Koivisto T, Ronkainen A, Rinne J, et al. Type 2 diabetes and risk of rupture of saccular intracranial aneurysm in Eastern Finland. Diabetes Care 2013; 36:2020–2026. https://doi.org/10.2337/dc12-1048 PMID: 23536581

14. Wermer MJ, van der Schaaf IC, Algra A, Rinkel GJ. Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: An updated meta-analysis. Stroke 2007; 38:1404–1410. https://doi.org/10.1161/01.STR.0000269555.51401.cd PMID: 17332442
15. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: Studies in a random population sample. British Medical Journal 1976; 2:554. PMID: 963430

16. Danielson M, Dammström B. The prevalence of secondary and curable hypertension. Acta Medica Scandinavica 1981; 209:451–455. PMID: 7257863

17. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertension Research 2004; 27:193–202. PMID: 15080378

18. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and how to screen? European heart journal 2014; 35:1245–1254. https://doi.org/10.1093/eurheartj/ehu354 PMID: 24366917

19. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney International 1997; 51:2–15. PMID: 8995712

20. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation 2005; 112:1362–1374. https://doi.org/10.1161/CIRCULATIONAHA.104.492348 PMID: 16129817

21. Mosso L, Carvaljal C, González A, Baraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161–165. https://doi.org/10.1161/01.HYP.0000079505.25750.11 PMID: 12796282

22. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: The most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58:811–817. https://doi.org/10.1161/HYPERTENSIONAHA.111.179788 PMID: 21968750

23. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015; 386:801–812. https://doi.org/10.1016/S0140-6736(14)61468-9 PMID: 25832858

24. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Journal of Hypertension 2013; 31:1281–1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc PMID: 23817082

25. Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: Development, rupture and preventive management. Nature Reviews Neurology 2016; 12:699–713. https://doi.org/10.1038/nrneurol.2016.150 PMID: 27808265

26. Ronkainen A, Hernesniemi J, Puranen M, Niemitukia L, Vanninen R, Ryynänen M, et al. Familial intracranial aneurysms. Lancet 1997; 349:380–384. https://doi.org/10.1016/S0140-6736(97)80009-8 PMID: 9033463

27. Tikkanen I, Tikkanen T. Prevalence of secondary hypertension. In: Current Care Guidelines, Duodecim [online]. http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=nix01436. Accessed June 12, 2017.

28. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: A meta-analysis. The Journal of clinical endocrinology and metabolism 2014; 99:923–931. https://doi.org/10.1210/jc.2013-2409 PMID: 24423323

29. Ohayon MM, Guilleminiault C, Priest RG, Caulet M. Snoring and breathing pauses during sleep: Telephone interview survey of a united kingdom population sample. BMJ 1997; 314:860–863. PMID: 9093095

30. Gissler M, Haukka J. Finnish health and social welfare registers in epidemiological research. Norsk Epidemiologi 2004; 14:113–120.